

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.9967 • KOHLBERG/MUBADALA/PARTNERS GROUP/PIONEER UK MIDCO 1

SECTION 1.2

Description of the concentration

On 1st October 2020, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation by which Kohlberg & Co., L.L.C., Mubadala Investment Company PJSC and Partners Group AG intend to indirectly acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of Pioneer UK Midco 1 Limited. The concentration is accomplished by way of an indirect acquisition of shares of Pioneer UK Midco 1 Limited.

The business activities of the parties are:

Kohlberg & Co., L.L.C.: a U.S. private equity management company specialised in investments in middle market companies. Kohlberg's portfolio companies are active in various industries, such as industrial manufacturing, consumer products, business services, healthcare services and financial services.

Mubadala Investment Company PJSC: an Abu Dhabi public joint stock company focused on investment and development across a variety of industries, including aerospace, ICT, semiconductors, metals and mining, renewable energy, oil and gas, petrochemicals, utilities, healthcare, real estate, pharma and medtech, agribusiness and a global portfolio of financial holdings.

Partners Group AG: Partners Group is a global private markets investment management company that is active in the areas of private equity, private real estate, private infrastructure and private debt.

Pioneer UK Midco I Limited: Pioneer UK Midco 1 Limited ("PUM1") is a holding company based in the UK. It owns and controls the group of companies doing business as PCI Pharma Services ("PCI"). PCI is a global provider of services to the pharmaceutical and biotech industries in three distinct areas: clinical trial services, commercial packaging, and development and manufacturing of pharmaceuticals.

Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË

Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.